A mother’s perspective on Sarepta’s gene therapy halt
How are families of patients reacting to the removal of Sarepta’s gene therapy from the market? Why are investors excited about narcolpesy drugs? And why has there been less financing in oncology startups?
We chat about all that and more on this on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We bring on a mother whose 7-year-old has Duchenne muscular dystrophy, and hear her thoughts on Sarepta’s decision to pull its treatment Elevidys from the market, following a request from the Food and Drug Administration.
Adam Feuerstein, Elaine Chen, and Allison DeAngelis
Go to statnews